Abiraterone/prednisone plus ADT for early prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests adding abiraterone (a hormone therapy pill) and prednisone to standard hormone therapy (ADT) for prostate cancer that has spread to nearby lymph nodes but is too small to see on regular scans. The goal is to see if this combination works better than ADT alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of prostate cancer that has not been treated yet.
- A special PET scan (PSMA-PET) shows a small lymph node with cancer in the pelvis (less than 1 cm).
- You are able to swallow pills.
- You are 30 years or older.
- You have no other serious health problems (like unstable heart disease, uncontrolled diabetes, or recent blood clots).
- You do not have cancer that has spread outside the pelvis (like to bones).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well abiraterone (a hormone-blocking medicine) plus prednisone (a steroid) works in people with metastatic, hormone-sensitive prostate cancer. It also looks at whether results differ by race/ethnicity and other health factors.
This trial tests combining radiation therapy with two hormone-blocking drugs (darolutamide and degarelix) to treat intermediate-risk prostate cancer. The goal is to see if this combination is more effective and safe than radiation alone.
This study tests a new form of abiraterone (a hormone therapy) against the standard one in men whose prostate cancer has spread and no longer responds to usual hormone treatment. Participants must have had limited prior treatments and be in decent overall health.
This study is comparing two drugs, abiraterone and darolutamide, to see how well they work for advanced prostate cancer. You might join if your cancer has spread and your doctor agrees these treatments could help.
This trial tests a new approach using radiation therapy (radiotherapy) combined with hormone therapy before the standard surgery to remove the prostate. It aims to see if this combination can better control prostate cancer that has spread to a few spots (oligometastatic) and improve outcomes.
This trial tests a new way to predict how well hormone therapy combined with newer drugs works for men with prostate cancer that has spread. It uses advanced tissue analysis to help tailor treatment.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.